FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 653 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Durable Antitumour Activity of Pembrolizumab Plus Lenvatinib in Patients with Previously... July 25, 2023 How to Tell If Cancer Information on Social Media Is “Fake... September 29, 2020 CCDI Activities Enhance NCI’s Childhood and AYA Cancer Research July 13, 2020 Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism July 5, 2023 Load more HOT NEWS After a Generous Donor Covered Her Bills, Breast Cancer Survivor Raises... ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical... Reunión anual de la American Society of Clinical Oncology de 2022:... Catch up on Behind the Science 2021 – From funding stream...
